Share this article
Share this article
ResearchAndMarkets.com s offering.
The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2021 to 2029. Neurotrophic keratitis is an orphan disease which is primarily caused due to the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings preset in the eye corneal region. Traditional therapies are employed to suppress the clinical manifestation occurring in different stages of the disease. Currently RGN-259 developed by ReGenTree, LLC. is in the phase III clinical trial study for the treatment of neurotrophic keratitis.